Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral adrenoleukodystrophy US trial with leriglitazone to commence in mid-2023 providing an FDA-approved route to US market whilst EMA evaluates European Marketing Authorization Application (MAA) Mataró, Barcelona,.
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib (MK-1026) – as well as KEYTRUDA® (pembrolizumab) in multiple blood cancersRAHWAY, N.J. (BUSINESS WIRE) $MRK #MRK Merck (NYSE: MRK), known as MSD outside of the United States and Ca.
01.12.2022 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from clinical trials and real-world studies at the upcoming 64th American Society of Hematology (ASH) Annual Meeting from Dec. .